Panacea Index Logo

Command Palette

Search for a command to run...

REM Sleep Behavior Disorder.

Frontiers of neurology and neuroscience
January 1, 2018
Claudio L Bassetti et al. (2 authors)
Journal ArticleReviewHuman Study
Study Details

Study Goal

The researchers aimed to evaluate the role of melatonin in the treatment of rapid eye movement sleep behavior disorder (RBD), including its efficacy and potential as part of pharmacological interventions.

Results Summary

The study mentions melatonin as one of the pharmacological treatments for RBD, alongside clonazepam, but does not provide specific efficacy data or comparative outcomes for melatonin alone.

Population

Adults with rapid eye movement sleep behavior disorder (RBD), including those with neurodegenerative disorders like Parkinson's disease.

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (4)
InterventionDirectionEndpointPopulationDosageImpactClaim #
alcoholism
increase
rapid eye movement sleep behavior disorder
patients
-
loss of physiological muscle atonia combined with dream enactment
#1
antidepressant treatment
increase
rapid eye movement sleep behavior disorder
patients
-
loss of physiological muscle atonia combined with dream enactment
#2
clonazepam
decrease
rapid eye movement sleep behavior disorder
patients
-
treatment
#3
melatonin
decrease
rapid eye movement sleep behavior disorder
patients
-
treatment
#4
Abstract

Rapid eye movement sleep behavior disorder (RBD) is a brain disorder, characterized by the dream enactment during rapid eye movement (REM) sleep due to a lack of physiologic muscle atonia and increased muscle twitching. Schenk was the first to describe this disorder in 1986; however, few authors reported in the 1970-1980s loss of physiological muscle atonia combined with dream enactment in the course of brainstem disorders and as a consequence of alcoholism and antidepressant treatment. RBD affects less than 1% of the adult population, but can be found in up to 25-50% of neurodegenerative disorders including Parkinson's disease, multisystem atrophy, and dementia with Lewy body. In the last decade, many studies provided evidence that RBD precedes parkinsonian motor signs by several years, suggesting that RBD should no longer be considered a complication but a part of the prodromal phase of these diseases. Etiologically, primary (idiopathic RBD) and several secondary forms in addition to neurodegeneration (related to focal brainstem damage, narcolepsy, autoimmune disorders, and drugs) are known. Pathophysiologically, brainstem and supratentorial mechanisms involving glutamatergic, glycinergic, and GABA-ergic neurotransmission have been implicated. Recently, an animal model of RBD has been described. Clinical features consist of characteristic nocturnal behaviors, but also daytime symptoms including excessive sleepiness and cognitive alterations. The diagnosis of RBD is made according to international diagnostic criteria, based on medical history, and video-polysomnographic features. Current treatment strategies include actions which ensure a safe sleep environment, the avoidance of triggering/exacerbating factors and if necessary pharmacological (mainly clonazepam and melatonin) and non-pharmacological (e.g., behavioral measures) interventions. Future research should clarify the exact sleep-wake characteristics of RBD (also beyond REM sleep) and their evolution over time, the contribution of brainstem but also supratentorial mechanisms to its pathophysiology, and the (early?) diagnostic and (causative?) treatment consequences of RBD in the context of neurodegeneration.

Medical Subject Headings (MeSH)
HumansREM Sleep Behavior Disorder
Study Links
Quality Scores
SafetyNot Assessed
Efficacy70/10
Quality80/10
Citation Metrics
Total Citations22
Citations/Year3.1
Relative Citation Ratio1.32
NIH Percentile60.4%
Research Impact Scores
APT Score0.50
Weight Score2.14
Normalized Score0.64
Related Supplements